



---

**ASX ANNOUNCEMENT**  
**19 NOVEMBER 2013**

**CHAIRMAN'S ADDRESS TO SHAREHOLDERS AT ANNUAL GENERAL MEETING**

Ladies and Gentlemen,

Welcome to the Annual General Meeting of Viralytics. Limited.

During the past year CAVATAK™ has attained a prominent profile at prestigious oncology conferences around the world. This is due to the development of exciting clinical data, most notably in our Phase 2 CALM trial in late stage melanoma patients.

On 18 September 2013 we announced that trial had attained its primary endpoint. We are very proud to achieve this key milestone in the development of CAVATAK™ which stems from the dedicated efforts of our team over several years. Very few Australian biotechnology companies have achieved a successful Phase 2 outcome in a US study with an oncology product. While that trial continues, we are also now considering the appropriate next step towards achieving registration for a CAVATAK™ melanoma product.

Following approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in September 2013 the company plans to commence a Phase 1/2 STORM (Systemic Treatment Of Resistant Malignancies) clinical trial for late stage melanoma, non-small cell lung, metastatic bladder and castrate-resistant prostate cancer. This follows the successful completion during the year of a Phase 1 study investigating the intravenous administration of CAVATAK™ in late stage cancer patients.

The Board is heartened by this growing body of clinical data. We are also excited by the accelerated patient recruitment in the CALM trial through 2013, a clear indication of growing clinician support for CAVATAK™.

In August 2013 we announced that the Company had listed on the OTCQX International Market in the United States and engaged Roth Capital Partners as our Principal American Liaison Bank. This is part of a broader strategy to promote the Company and its technology in the United States.



I would like to thank fellow directors Peter Molloy and Dr Phillip Altman who stepped up in an Executive capacity for the 6 months the company was without a Chief Executive prior to Dr McColl's commencement. Dr Len Post also has proved to be an invaluable counsel within the Board and with the R&D team throughout the period. His experience taking product successfully through FDA approval with Onyx Pharmaceuticals Inc. and his role as Director at BioVex Inc. through the period when they were acquired by Amgen, provides the Viralytics team with a vital resource as it progresses CAVATAK™ along the clinical and commercial pathway.

Shortly our CEO Dr Malcolm McColl will make his first presentation to an AGM of this Company. He will outline the company's plans to deliver shareholder value in the coming years, building off the excellent progress made in the last 12 months.

Dr McColl commenced as Chief Executive Officer of the Company in January 2013. He has brought an added drive to the Company's activities, reflected in the increased patient recruitment and in active engagement with a variety of key opinion leaders and decision makers in the oncology space. As the company increases its focus on business development we expect Dr McColl's skills and experience will be a key factor in attaining strong commercial outcomes for the company and its shareholders.

In conclusion I would like to thank Dr McColl, Chief Scientific Officer Professor Darren Shafren, and their teams for continued sterling efforts in the past year. I am confident the coming year will see further significant milestones achieved through their efforts.

Paul Hopper  
**Chairman**  
**Viralytics Limited**